Episode 189 - July 17, 2026

What It Covers

Biotech Hangout Episode 189 covers Eli Lilly's $3.8B Atai acquisition, Roivant's upcoming brepacitinib launch for dermatomyositis, China's rising first-in-class drug innovation, Kalshi's clinical trial betting markets, Merck's oral PCSK9 inhibitor approval, and Biogen's mixed Phase 2 tau-targeting ASO data in Alzheimer's disease.

Key Questions Answered

• •Eli Lilly's expansion strategy: Lilly's acquisition of Atai for $2.8B upfront plus $1B CVR signals a deliberate pivot toward disease prevention over treatment, modeled on Silicon Valley playbooks. Investors and competitors should monitor how Lilly's LillyDirect telehealth platform bypasses PBMs, as this direct-to-consumer infrastructure may redefine commercial models across large-cap pharma over the next decade.
• •Brepacitinib launch pricing framework: Roivant positions brepacitinib, a JAK1/TYK2 oral inhibitor for dermatomyositis, between two pricing benchmarks: IVIG at roughly $225K annually and VivGuard at approximately $870K gross. Expect net pricing closer to the lower bound. With 20–40% of patients already on off-label JAK inhibitors, physician warehousing creates an accelerated early-adoption dynamic worth tracking at launch.
• •China drug innovation shift: BioCentury data shows 40% of new INDs originating from China in 2026 are now first-in-class, up from prior years. Rather than treating this as a geopolitical risk, US biotech teams should evaluate Chinese assets on a case-by-case basis, scrutinizing manufacturing site quality and clinical data reproducibility rather than applying blanket country-level judgments.
• •Kalshi clinical trial prediction markets: Kalshi's new venue allows betting on Phase 3 outcomes and regulatory approvals for companies above $500M market cap, with insider trading guardrails. Brepacitinib currently carries an 81% approval probability on the platform. Biotech legal and compliance teams should immediately review whether existing insider trading policies extend to these prediction market instruments for employees.
• •ASO tolerability limits tau data interpretation: Biogen and Ionis's Phase 2 dronersen data showed an inverted dose response, with the lower dose outperforming the higher dose on ADAS-Cog and CDR-SB at 76 weeks. This pattern mirrors prior ASO CNS failures and suggests tolerability, not target biology, drove the confounded results. Tau remains a viable target; non-ASO modalities like Arrowhead's BBB-shuttle siRNA deserve closer attention.